PIA
UTMD icon

Piedmont Investment Advisors’s Utah Medical Products UTMD Stock Holding History

Piedmont Investment Advisors’s Portfolio UTMD Stock Details UTMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-60
Closed -$7K – 2225
2018
Q2 		$7K Buy
+60
New +$6.27K ﹤0.01% 1991

Other funds holding UTMD

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Lazard Asset Management
Lazard Asset Management New York $60.8B AUM 22.47% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AA
Ancora Advisors Cleveland, Ohio $4.7B AUM 19.05% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return

Piedmont Investment Advisors's UTMD Position: Q3 2018 in Review

Piedmont Investment Advisors sold out of Utah Medical Products (UTMD) in Q3 2018, closing a stake of 60 shares — an estimated $7K sold.

Piedmont Investment Advisors first reported a position in UTMD in Q2 2018 and held it in 1 quarter. The position peaked at $7K in Q2 2018. 90 funds tracked by Wall St. Rank hold UTMD as of Q3 2018.

  • Piedmont Investment Advisors reported no remaining Utah Medical Products position as of Q3 2018 after selling out during the quarter.
  • Piedmont Investment Advisors sold 60 Utah Medical Products shares in Q3 2018, an estimated $7K.
  • Piedmont Investment Advisors first reported a position in Utah Medical Products in Q2 2018 and held it in 1 quarter.
  • Piedmont Investment Advisors's Utah Medical Products position peaked at $7K in Q2 2018.
  • 90 funds tracked by Wall St. Rank held Utah Medical Products as of Q3 2018.

Based on Piedmont Investment Advisors's 13F filing for Q3 2018, filed 8 Nov 2018.